Diligence memo · auto-generated · as of July 2, 2026
BioPharmX Corp
BioPharmX Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
BioPharmX Corp operates in Pharmaceuticals, based in Menlo Park.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BioPharmX Corp has raised $11M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.9M on 2014-04-11.
Most recent recorded round closed around 2016-09-25.
Valuation (modeled)modeled
Provath models BioPharmX Corp at approximately $29M (range $1.1M–$157M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.16× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 9.8 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 6.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 56% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.